RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity  by Manczak, Maria & Reddy, P. Hemachandra
Biochimica et Biophysica Acta 1832 (2013) 2368–2378
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isRNA silencing of genes involved in Alzheimer's disease enhances
mitochondrial function and synaptic activityMaria Manczak a, P. Hemachandra Reddy a,b,⁎
a Neurogenetics Laboratory, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA
b Department of Physiology and Pharmacology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA⁎ Corresponding author at: Neurogenetics Laboratory, D
National Primate Research Center, Oregon Health & Scie
Avenue, Beaverton, OR 97006, USA. Tel.: +1 503 629 404
E-mail address: reddyh@ohsu.edu (P.H. Reddy).
0925-4439/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2013.09.008a b s t r a c ta r t i c l e i n f oArticle history:
Received 31 May 2013
Received in revised form 26 August 2013
Accepted 16 September 2013
Available online 21 September 2013
Keywords:
RNA silencing
Amyloid precursor protein
Tau
Voltage-dependent anion channel
Human neuroblastoma cell
Immunoblotting analysisAn age-dependent increase in mRNA levels of the amyloid precursor protein (APP), the microtubule-associated
protein Tau, and voltage-dependent anion channel 1 (VDAC1) genes are reported to be toxic to neurons affected
by Alzheimer's disease (AD). However, the underlying toxic nature of these genes is not completely understood.
The purpose of our studywas to determine the effects of RNA silencing of APP, Tau, and VDAC1 genes in AD path-
ogenesis. Using human neuroblastoma (SHSY5Y) cells, we ﬁrst silenced RNA for APP, Tau, and VDAC1 genes, and
thenperformed real-timeRT-PCR analysis tomeasuremRNA levels of 34 genes that are involved inADpathogen-
esis. Using biochemical assays, we also assessed mitochondrial function bymeasuring levels of H2O2 production,
lipid peroxidation, cytochrome c oxidase activity, ATP production, and GTPase enzymatic activity.We found that
increased mRNA expression of synaptic function and mitochondrial ﬁssion genes, and reduced levels of mito-
chondrial fusion genes in RNA silenced the SHSY5Y cells for APP, Tau and VDAC1 genes relative to the control
SHSY5Y cells. In addition, RNA-silenced APP, Tau, and VDAC1 genes in SHSY5Y cells showed reduced levels of
H2O2 production, lipid peroxidation, ﬁssion-linked GTPase activity, and increased cytochrome oxidase activity
and ATP production. These ﬁndings suggest that a reduction of human APP, Tau, and VDAC1 may enhance syn-
aptic activity, may improve mitochondrial maintenance and function, and may protect against toxicities of AD-
related genes. Thus, these ﬁndings also suggest that the reduction of APP, Tau, and VDAC1 mRNA expressions
may have therapeutic value for patients with AD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common cause of mental
dementia in the aged population. AD is characterized by the progressive
decline of memory and multiple cognitive functions, as well as changes
in behavior and personality [1–3]. Histopathological examination of
postmortem brains fromAD patients has revealed extracellular amyloid
deposits and intracellular neuroﬁbrillary tangles that occur late in dis-
ease progression. AD is also associated with inﬂammatory responses,
synaptic damage, changes in hormonal levels, and mitochondrial struc-
tural and functional abnormalities [4–9]. The best correlate that has
been found to the loss of memory and cognitive decline in AD patients
is synaptic loss [10–13]. However, the molecular events leading to
synaptic loss in AD are unknown. Recent evidence suggests that Aβ
accumulates in the synapses and synaptic mitochondria and that this
accumulation may be critically responsible for synaptic damage and
cognitive dysfunction in AD patients [7,8,12].ivision of Neuroscience, Oregon
nce University, 505 NW 185th
5; fax: +1 503 418 2701.
ights reserved.In the last decade, tremendous progress has been made in under-
standing basic biology, disease progression, and therapeutics of AD.
Multiple therapeutic approaches are being developed and tested to
slow and/or prevent cognitive decline in AD patients. Using experimen-
tal mouse models and humans in clinical trials researchers are investi-
gating cellular changes found in postmortem brains of AD patients, in
brain tissues from AD mouse models, and cellular changes in mouse
and human primary neurons and brain cells in such therapeutic ap-
proaches as Aβ-immunotherapy, anti-inﬂammatory therapy, anti-
oxidant therapy, hormonal therapy, cholinergic therapy, inactivation
of GSK3β, and cell cycle therapy [14–28]. Although tremendous prog-
ress has been made in elucidating the effects of AD therapeutics on
the disease process in AD, researchers still have not identiﬁed early
detectable markers of AD, and they have not yet identiﬁed agents or
drugs capable of delaying or preventing dementia in AD patients.
Increasing evidence suggests that an age-dependent, progressive in-
crease in the accumulation of synaptic damage, inﬂammatory responses
of brain, andmitochondrial structural and functional abnormalitiesmay
be responsible for neuronal damage found in the brains of AD patients
and of AD mouse models [1,7,28–32]. In both types of brains, increased
expression levels of AD-related genes have been associated with the
progression of AD. These genes include VDAC1, ANT, CypD, APP, PS1,
BACE1, and Tau [6,33–43]. Further, recent genetic studies have revealed
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brain and is sufﬁcient to cause AD [44]. In studies of brains from
Down Syndrome patients who carry an extra APP gene, increased ex-
pression of APP and Aβ deposits has been reported [45], suggesting
that normal, extra APP genes are sufﬁcient to increase Aβ pathology in
these patients.
Recently, investigators have suggested that the reduction of gene
expressions associated with AD may be responsible for the reduction
of toxic accumulations of Aβ and phosphorylated Tau, resulting in the
slowing of AD progression [46,47]. In studies of RNA silencing (siRNA)
in AD, researchers silenced AD genes, and APP [48,49], Tau [48–50],
PS1 [51], and BACE1 genes [46,52]. They found that, in every case, this
silencing resulted in the reduction of mRNA levels of targeted genes
[46–52], indicating successful application of SiRNA technology to the
AD process.
In several studies usingAD transgenicmousemodels andAD-related
genes, the silencing of APP resulted in reduced levels of Aβ and the
amelioration of cognitive deﬁcits in the mice [48,49,53–55], strongly
suggesting a promising therapeutic value for APP silencing in AD
patients. However, the underlying mechanisms in reducing synaptic
dysfunction and amelioration of cognitive deﬁcits are not completely
understood.
Further, in our recent mitochondrial, Aβ, and Tau studies of the
mitochondrial outer membrane protein VDAC1, we studied VDAC1 in
postmortem brains from AD patients and APP transgenic mice, and we
found increased levels of VDAC1 and an increase in the interaction
between VDAC1 and Aβ, between VDAC1 and phosphorylated Tau,
and between VDAC1 and mitochondrial dysfunction, indicating VDAC1
toxicity in AD progression [56]. However, the effect of RNA silencing of
APP, Tau, and VDAC1 genes on AD-related synaptic activity and mito-
chondrial function is not known.
In the current study, we sought to determine: 1) the effects of RNA
silencing of APP, Tau, and VDAC1 genes on mRNA levels in studies of
genes related to synapses, mitochondria, andAD in humanneuroblasto-
ma (SHSY5Y) cells relative to control SHSY5Ycells, and 2)mitochondrial
function in RNA-silenced APP, Tau, and VDAC1 genes in SHSY5Y cells
by measuring free radical production, lipid peroxidation, cytochrome
oxidase activity, ATP production, and GTPase enzymatic activity in
SHSY5Y cells relative to the control SHSY5Y cells.
2. Materials and methods
The human neuroblastoma (SHSY5Y) cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA) and cultured
for 7 days in a medium (1:1 mixture of DMEM and OptiMEM, 10% FBS
plus penicillin and streptomycin) (Invitrogen, Carlsbad, CA). The cells
were used for SiRNA of human APP, human Tau, and VDAC1 genes.
2.1. RNA silencing of human APP, Tau, and VDAC1 genes
The SHSY5Y cells (0.3 × 106)were seeded perwell in a 6-well culture
plate, in amedium containingOpt-MEM,DMEM, 10% FBS, and antibiotics
(1× Pen & Strep). The cells were grown until they reached 70–80% con-
ﬂuence. The growth medium was replaced with a reduced serummedi-
um without antibiotics. We used SiRNA reagents (Invitrogen) to silence
human APP, Tau, and VDAC1 genes in the SHSY5Y cells, following
manufacturer's instructions. The targeted RNA sequences that we used
for (a) APP, (b) Tau, and (c) VDAC1 were, respectively: (a) APP/si 1500,
sense: 5′ CAAGGAUCAGUUACGGAAATT 3′ and antisense: 5′ UUUCCG
UAACUGAUCCUUGGT 3′; (b) Tau/si 8508, sense: 5′ CAUCCAUCAUAAA
CCAGGATT 3′ and antisense: 5′ UCCUGGUUUAUGAUGGAUGTT 3′; and
(c) VDAC1/si 14768, sense: 5′ GAAUACCGACAAUACACUATT 3′ and anti-
sense: 5′ UAGUGUAUUGUCGGUAUUCCA 3′; control GAPDH/4390849,
sense: 5′ GGUCAUCCAUGACAACUUUTT 3′ and antisense: 5′ AAAGUUG
UCAUGGAUGACCTT 3′.Brieﬂy, 4 μl Lipofectamine 2000 was used in a 50- μl Opti-MEM
reagent with reduced serum; and 10 nM SiRNA was added to the
tube. The contents were mixed gently for 20 min at room temperature
to allow the SiRNA–Lipofectamine 2000 complex to form. This complex
was added to each well. The cells were incubated for 74 h at 37 °C in a
CO2 incubator. The transfected cellswere harvested and their RNA levels
examined for the mRNA levels in APP, Tau, and VDAC1. Using protein
lysates,we alsomeasured APP, Tau, and VDAC1 proteins, andmitochon-
drial functional parameters, including levels of hydrogen peroxide
(H2O2), lipid peroxidation, GTPase activity, cytochrome c oxidase activ-
ity, and ATP production. Four independent cell-culture experiments
were conducted for each of SiRNA-APP, SiRNA-Tau, and SiRNA-VDAC1
in the SHYS5Y cells and the control SHSY5Y cells.
2.2. Real-time RT-PCR analysis
Using the reagent TriZol (Invitrogen), we isolated total RNA from all
lines of cells (SiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, and SHSY5Y cells).
Using primer express Software (Applied Biosystems, Foster City, CA),
we designed the oligonucleotide primers for the housekeeping genes
β-actin and GAPDH; the mitochondrial-encoded electron transport
chain (ETC) genes (Complex I — ND3 & ND6, Complex III — CytB, Com-
plex IV — COX1 & 2, and Complex V — ATP6); the mitochondrial struc-
tural ﬁssion genes Drp1 and Fis1; the mitochondrial structural fusion
genes MFN1, MFN2, Opa1, VDAC1, and ANT; the mitochondrial matrix
genes CypD and BcLxL; hexokinase 1 and hexokinase 2; the synaptic
genes synaptophysin, PSD95, synapsin 1, synapsin 2, synaptobrevin 1
and 2, GAP43, synaptopodin, and neurogranin; and the AD-related
APP, Tau, PS1, PS2, BACE1, GSK3α, and GSK3β genes. The primer se-
quences and amplicon sizes are listed in Table 1.
mRNA expression of the genesmentioned abovewasmeasuredwith
SYBR-Green chemistry-based quantitative real-time RT-PCR, as previ-
ously described in Gutala and Reddy [57] and Reddy et al. [58]. Brieﬂy,
2 μg of DNAse-treated total RNA was used as the starting material, to
which was added 1 μl of oligo (dT), 1 μl of 10 mM dNTPs, 4 μl of 5×
ﬁrst strand buffer, 2 μl of 0.1 M DTT, and 1 μl RNAse out. The reagents
RNA, dT, and dNTPs were mixed and heated at 65 °C for 5 min. They
were then chilled on ice until the remaining components were added.
The samples were incubated at 42 °C for 2 min, and then 1 μl of Super-
script III (40 U/μl) was added. The samples were incubated at 42 °C
for 50 min, at which time the reaction was inactivated by heating the
samples at 70 °C for 15 min.
Quantitative real-time PCR ampliﬁcation reactions were performed,
using RNA from the SiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, SHSY5Y, and
SHSY5Y cells, and an ABI Prism 7900 sequence detection system
(Applied Biosystems), in a 25-μl volume of total reaction mixture. The
reaction mixture consisted of 1× PCR buffer containing SYBR-Green;
3 mM MgCl2; 100 nm of each primer; 200 nm of dATP, dGTP, and
dCTP each; 400 nm of dUTP; 0.01 U/μl of AmpErase UNG; and
0.05 U/μl of AmpliTaq Gold. A 20 ng cDNA template was added to
each reaction mixture.
The CT-values ofβ-actin and the GAPDHwere tested to determine the
unregulated endogenous reference genes in the SiRNA-APP, SiRNA-Tau,
and SiRNA-VDAC1 cells. The CT-value is an important quantitative pa-
rameter in real-time PCR analysis [57]. All RT-PCR reactions were carried
out in triplicate,with no template control. The PCR conditionswere: # cy-
cles at 50 °C for 2 min and then at 95 °C for 10 min, followed by 40 cy-
cles at 95 °C for 15 s and 60 °C for 1 min. The ﬂuorescent spectra were
recorded during the elongation phase of each PCR cycle. To distinguish
speciﬁc amplicons from non-speciﬁc ampliﬁcations, a dissociation curve
was generated. The CT-values were calculated with sequence-detection
system software V1.7 (Applied Biosystems). We used an automatic set-
ting of base line, which was the average value of PCR, cycles 3–15, plus
CT generated 10 times its standard deviation. The ampliﬁcation plots
and CT-values were exported from the exponential phase of PCR directly
into a Microsoft Excel worksheet for further analysis.
Table 1
Summary of real-time RT-PCR oligonucleotide primers used in measuring mRNA expres-
sion, in mitochondrial genes, AD-related genes, and synaptic genes in SHSY5Y cells after
RNA silencing.
Gene DNA sequence (5′–3′) PCR product
size
Mitochondrial-structural genes
Drp1 Forward primer TGGGCGCCGACATCA 54
Reverse primer GCTCTGCGTTCCCACTACGA
Fis1 Forward primer TACGTCCGCGGGTTGCT 54
Reverse primer CCAGTTCCTTGGCCTGGTT
MFN1 Forward primer GGCATCTGTGGCCGAGTT 56
Reverse primer ATTATGCTAAGTCTCCGCTCCAA
MFN2 Forward primer GCTCGGAGGCACATGAAAGT 61
Reverse primer ATCACGGTGCTCTTCCCATT
Opa1 Forward primer GTGCTGCCCGCCTAGAAA 65
Reverse primer TGACAGGCACCCGTACTCAGT
VDCA1 Forward primer GCCCTACCTGATTGGTGCAA 69
Reverse primer TTCAAGCTCCCTGGCAGAA
ANT Forward primer CACCCATCGAGAGGGTCAA 54
Reverse primer ATTTGCTTGCTGGCATGCT
Cyclophilin D Forward primer AGCCCTCCAACCCCAGTAA 57
Reverse primer CGCTCCCCTCCGATGTC
BcL2-XL Forward primer CTTTTGTGGAACTCTATGGGAACA 69
Reverse primer CAGCGGTTGAAGCGTTCCT
ANT Forward primer GCCAACGTGATCCGTTACTTC 68
Reverse primer GAGCTGCTTGTACTTGTCCTTGAA
Mitochondrial-encoded electron transport chain genes
ND3-CI Forward primer AGAAAAATCCACCCCTTACGAGT 64
Reverse primer TGGAGAAAGGGACGCGG
ND6-CI Forward primer CCAAGACCTCAACCCCTGAC 77
Reverse primer
TGGTTGTCTTTGGATATACTACCAGCG
CYT B-CIII Forward primer CCCCACCCCATCCAACAT 61
Reverse primer TCAGGCAGGCGCCAAG
COX 1-CIV Forward primer TCCGCTACCATAATCATCGCT 67
Reverse primer CCGTGGAGTGTGGCGAGT
COX 2-CIV Forward primer TGCCCGCCATCATCCTA 63
Reverse primer TCGTCTGTTATGTAAAGGATGAGT
ATP6-CV Forward primer CCAATAGCCCTGGCCGTAC 72
Reverse primer CGCTTCCAATTAGGTGCATGA
AD-related genes
APP Forward primer TGTCCGCGCAGAACAGAA 56
Reverse primer CGCACATGCTCGAAATGC
PS1 Forward primer ACCTGCCTTCCAACATTGAATT 68
Reverse primer CCAGCCCAAGGGCAAAA
PS2 Forward primer GGAGCGAAGCACGTGATCA 63
Reverse primer TGGCTACCACCACGATCATG
Tau Forward primer TGTGTCAGGGCACAGACTAGGT 74
Reverse primer GGGCTATGACCAGAGAGAACCAT
BACE1 Forward primer
GATCCTGAACAAGAAAGAGTAACACTGA
70
Reverse primer GGAGGATAAGTGTTTTGG
Hexokinase 1 Forward primer CCAGCAGCTAGGTCTGAATAGCA 61
Reverse primer CCCCGCACACTGTCTTGAC
Hexokinase 2 Forward primer GAGGCAGCATGGGATAATGG 63
Reverse primer AAGAGAACCCTTGTCCCTCTACTTT
GSK-3α Forward primer TTCCCCCTCTCTTCAACTTCAG 57
Reverse primer GCGTTGAGAGACGGTTGGA
GSK-3β Forward primer
CAGCTGTTCCGAAGTTTAGCCTATAT
85
Reverse primer TCAGGATCCAACAAGAGGTTCTG
Synaptic genes
Synaptophysin Forward primer CATTCAGGCTGCACCAAGTG 59
Reverse primer TGGTAGTGCCCCCTTTAACG
PSD95 Forward primer TCGTCCCGGGAGAAAATG 57
Reverse primer GGCCGGCCTCAATGAACT
Synapsin 1 Forward primer ACCCCAATCACAAAGAAATGCT 62
Reverse primer CGTGCCCCATCTTCACAAC
Synapsin 2 Forward primer GCACCTATGCTGTGGATATGCA 59
Reverse primer GGAAGGACCGGACAACCTTT
Synaptobrevin
1
Forward primer GCAGGCAGGAGCATCACAAT 66
Reverse primer
GTTTTTCCACCAATACTTCCTCTTTAG
Synaptobrevin
2
Forward primer CGCAAATCACTCCCAAGATGA 65
Reverse primer CACCTGCAGATAATGTCGTGCTA
Table 1 (continued)
Gene DNA sequence (5′–3′) PCR product
size
Neurogranin Forward primer CCCCAGCGCACTGTTGA 58
Reverse primer CGCTCGGCGTTTGCAT
GAP43 Forward primer
AGATGGTATCAAACCAGAAGATAAAGC
65
Reverse primer CCACGGAAGCTAGCCTGAAT
Synaptopodin Forward primer TCCAGCCCAACACCCTAGTG 54
Reverse primer GCTGCTCGCCCAGACATC
Housekeeping genes
Beta actin Forward primer
GACAGTGTTGTGGGTGTAGGTACTAAC
67
Reverse primer CCGCTTTACACCAGCGTCAT
GAPDH Forward primer ATGGAAATCCCATCACCATCTT 56
Reverse primer CGCCCCACTTGATTTTGG
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GAPDH at each dilution. The standard curve was the normalized
mRNA transcript level, plotted against the log-value of the input cDNA
concentration at each dilution. To compare β-actin, GAPDH, and genes
of interest, relative quantiﬁcation was performed according to the
CT method (Applied Biosystems) [57,58]. Brieﬂy, the comparative CT
method involved the averaging of triplicate samples, which were
taken as the CT values for β-actin, GAPDH, mitochondrial, synaptic,
and AD-related genes. β-Actin normalization was used in the present
study because β-actin CT values were similar for the mitochondrial,
synaptic, and AD-related genes in the SHSY5Y, SiRNA-APP, SiRNA-Tau,
and SiRNA-VDAC1 cells. The ΔCT-value was obtained by subtracting
the average β-actin CT value from the average CT-value for the mito-
chondrial, synaptic, and AD-related genes. The ΔCT of the SHSY5Y cells
was used as the calibrator. Fold change was calculated according to
the formula 2−(ΔΔCT), where ΔΔCT is the difference between ΔCT and
the ΔCT calibrator value. To determine the statistical signiﬁcance of
mRNA expression between SHSY5Y and SiRNA-APP, SHSY5Y and
SiRNA-Tau, and SHSY5Y and SiRNA-VDAC1, the differences in CT values
between SHSY5Y and SiRNA-APP, SHSY5Y and SiRNA-Tau, and SHSY5Y
and SiRNA-VDAC1were used in relation to the normalization of β-actin.
Statistical signiﬁcance was calculated using a student's t test.2.3. Immunoblotting analysis
To determine whether reduced mRNA levels in SiRNA incorporate
human neuroblastoma cells, we performed immunoblotting analyses
of protein lysates prepared from SiRNA-APP, SiRNA-Tau, SiRNA-
VDAC1, and SHSY5Y cells. Twenty μg protein lysates were resolved on
a 4–12% Nu-PAGE gel (Invitrogen). These resolved proteins were trans-
ferred to PVDF (Novax Inc, San Diego, CA) and then incubated with a
blocking buffer (5% dry milk dissolved in a TBST buffer) for 1 h at
room temperature. The nylon membranes were incubated overnight
with primary antibodies of APP (6E10 — 1:400 mouse monoclonal;
Covance, San Diego, CA), Tau (1:200, Mouse Monoclonal, Pierce
Biotechnology, Inc. Rockford, IL), VDAC1 (1:400 rabbit polyclonal;
Abcam, Cambridge, MA), and beta actin (1:500, mouse monoclonal;
Sigma-Aldrich, St. Louis, MO).
The membranes were washed with a TBST buffer 3 times at 10-min
intervals and then incubated for 2 h with appropriate secondary
antibodies, followed by 3 additional washes at 10-min intervals. The
APP, Tau, and VDAC1 proteins were detected with the Supersignal West
Pico chemiluminescent reagent (Thermo Scientiﬁc, Rockford, IL). Scanned
images of the exposedX-rayﬁlmwere analyzedwith ImageJ to determine
relative band intensity. Quantiﬁcationwas performed onwestern blots of
protein lysates from SiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, and SHSY5Y
cells. Comparisons were made between SHSY5Y and SiRNA-APP,
SHSY5Y and SiRNA-Tau, and SHSY5Y and SiRNA-VDAC1.
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We assessedmitochondrial function bymeasuring H2O2 production,
cytochrome c oxidase activity, mitochondrial ATP, lipid peroxidation,
and GTPase activity in SiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, and
SHSY5Y cells.
2.3.1.1. H2O2 production. H2O2 production was measured in isolated mi-
tochondria from the SiRNA-APP, Si-RNA-Tau, SiRNA-VDAC1, and
SHSY5Y cells with an Amplex® Red H2O2 Assay Kit (Molecular Probes),
as previously described [56]. Brieﬂy, measurement of H2O2 production
was in isolated mitochondria from the SiRNA-APP and SHSY5Y cells. A
BCA Protein Assay Kit (Pierce Biotechnology) was used to measure pro-
tein concentration in mitochondrial proteins (μg/μl), Amplex Red re-
agents (50 μM), horseradish peroxidase (0.1 U/ml), and a reaction
buffer (1×). The mixture was incubated at room temperature for
30 min, followed by spectrophotometer readings of ﬂuorescence
(570 nm). H2O2 production was then determined, using a standard
curve equation expressed in nmol/μg mitochondrial protein. Four sepa-
rate individual experiments were conducted to measure H2O2
production.
2.3.1.2. Cytochrome oxidase activity. Cytochrome oxidase activity was
measured in isolated mitochondria from SiRNA-APP, SiRNA-Tau, SiRNA-
VDAC1, and SHSY5Y cells, as described in Manczak et al. [42,56]. Enzyme
activity was assayed spectrophotometrically with a Sigma Kit (Sigma-Al-
drich) following manufacturer's instructions. Brieﬂy, 2 μg mitochondrial
protein was added to 1.1 ml of a reaction solution containing 50 μl
0.22 mM ferricytochrome c fully reduced by sodium hydrosulphide,
Tris–HCl at pH 7.0, and 120 mM potassium chloride. WavelengthTable 2
mRNA fold changes of mitochondrial, synaptic, and AD-related genes in SiRNA–APP,
SiRNA–tau, and SiRNA–VDAC1, in SHSY5Y cells relative to control SHSY5Y cells.
Types of genes Genes mRNA fold changes
SiRNA
APP
SiRNA
VDAC
SiRNA
tau
AD-related genes APP −1.6⁎⁎ −1.4⁎ −1.7⁎
VDAC −1.3⁎ −1.8⁎⁎ −1.4⁎
Tau −1.1 −1.2 −1.4⁎
BACE 1 −1.5⁎⁎ −1.4⁎ −1.8⁎⁎
Presenilin 1 −1.4⁎ −1.6⁎ −1.8⁎⁎
Presenilin 2 −1.4⁎ −1.6⁎ −1.7⁎
Hexokinase 1 1.4⁎ 1.2 1.1
Hexokinase 2 1.0 1.1 1.1
GSK-3α −1.1 −1.3⁎ −1.5⁎
GSK-3β −1.3⁎ −1.2 −1.3⁎
Synaptic genes Synaptophysin 1.6⁎ 1.6⁎ 1.8⁎⁎
PSD-95 2.4⁎⁎ 1.4⁎ 1.3⁎
Synapsin 1 1.3 2.7⁎⁎ 2.2⁎⁎
Synapsin 2 4.6⁎⁎ 1.8⁎⁎ 2.0⁎⁎
Synaptobrevin 1 2.5⁎⁎ 1.4⁎ 4.2⁎⁎
Synaptobrevin 2 3.5⁎⁎ 2.8⁎⁎ 1.3
Neurogranin 3.1⁎⁎ 1.6⁎ 1.4⁎
GAP43 3.3⁎⁎ 1.2 4.4⁎⁎
Synaptopodin 2.8⁎⁎ 1.9⁎⁎ 1.6⁎
Mitochondrial
dynamics genes
DRP1 −1.3⁎ −1.2 −1.2
FIS1 −1.5⁎⁎ −1.3 −1.3
Mfn1 2.2⁎⁎ 1.5⁎ 1.2
Mfn2 1.7⁎ 1.8⁎⁎ 1.4⁎
Cyclophilin D −2.3⁎⁎ −1.2 −1.7⁎
OPA1 1.1 1.0 1.5⁎
BCL-XL 1.3 1.0 2.5⁎⁎
ANT −1.6⁎ −1.9⁎⁎ −1.5⁎
Mitochondrial-encoded
electron transport chain
genes
ND3-Complex I 1.2 1.2 1.1
ND6-Complex I 1.5⁎ 1.3 1.2
CytB-Complex III −1.2 −1.1 −1.5⁎
COX1-Complex IV −1.3 −1.3 −1.7⁎
COX2-Complex IV −1.3 −1.2 −1.4⁎
ATP6-Complex V 1.4⁎ 1.3 1.0
⁎ Represents P b 0.05 levels of signiﬁcance.
⁎⁎ Represents P b 0.005 level of signiﬁcance.absorbance at 550 mM (or its decrease) was recorded in 1-min reactions
at 10-s intervals. Cytochrome c oxidase activity was measured according
to the following formula: mU/mg total mitochondrial protein = (A/min
sample − [A/min blank] × 1.1 mL × 21.84). Protein concentrations
were determined, following the BCA method. Four separate individual
experiments were performed to measure cytochrome c oxidase activity.
2.3.1.3. ATP levels. Levels of ATPweremeasured in isolatedmitochondria
from the SiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, and SHSY5Y cells, with
anATPdetermination kit (Molecular Probes) [59]. This bioluminescence
assay was based on the reaction of ATPwith recombinant ﬁreﬂy lucifer-
ase and its substrate, luciferin. Luciferase catalyzes the formation of light
fromATP and luciferin. Luciferin is the emitted light that is linearly relat-
ed to the concentration of ATP, which is measured with a luminometer.
We measured ATP from mitochondrial pellets, using a standard curve
method. Four separate individual experiments were run to measure
ATP production.
2.3.1.4. Lipid peroxidation assay. Lipid peroxidates are unstable indicators
of oxidative stress in neurons [60]. 4-Hydroxy-2-nonenol (HNE) is the
ﬁnal product of lipid peroxidation. HNEwasmeasured in the protein ly-
sates prepared from SiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, and SHSY5Y
cells, with anHNE-His ELISA Kit (Cell BioLabs, Inc., San Diego, CA). Brief-
ly, freshly prepared protein was added to a 96-well protein binding
plate andwas incubated overnight at 4 °C. The proteinwas thenwashed
3 times with a wash buffer. An anti-HNE-His antibodywas added to the
wells, incubated for 2 h at room temperature, and thenwashed 3 times.
The samples were incubatedwith a secondary antibody that was conju-
gated with peroxidase for 2 h at room temperature. The samples were
then incubated with an enzyme substrate. Optical density was mea-
sured to quantify the level of HNE.
2.3.1.5. Fission-linked GTPase enzymatic activity.Using a Novus Biological
Calorimetric Kit (Littleton, CO), wemeasured GTPase enzymatic activity
in the protein lysates prepared from SiRNA-APP, SiRNA-Tau, SiRNA-
VDAC1, and SHSY5Y cells, following GTPase assay methods described
in Shirendeb et al. [61]. The enzymatic activity was based on Drp1
hydrolyzing GTP to GDP and to inorganic phosphorous (Pi). GTPase ac-
tivity was measured, based on the amount of Pi that the GTP produced.
By adding the ColorLock Gold (orange) substrate to the Pi generated
from GTP, we were able to assess GTP activity, based on the inorganic
complex solution (green). Calorimetric measurements (green) were
read in thewavelength range of 650 nm. GTPaseDrp1 activitywasmea-
sured in the SiRNA-APP, SiRNA-Tau, SiRNA-VDAC, and SHSY5Y cells.
Four separate individual experiments were performed to measure
GTPase activity.
2.4. Statistical analysis for mitochondrial functional parameters
Statistical analysis was performed for H2O2 production, cytochrome
c oxidase activity, 4-hydroxy-nonenol (lipid peroxidation), ATP produc-
tion, and GTPase activity. Data were collected from four cell-culture and
SiRNA experiments for the above-mentioned mitochondrial functional
parameters. We used a student's t-test and assessed statistical signiﬁ-
cance between SiRNA-APP and SHSY5Y cells, SiRNA-Tau and SHSY5Y
cells, and SiRNA-VDAC1 and SHSY5Y cells for all mitochondrial func-
tional parameters.
3. Results
3.1. APP: mitochondrial structural genes
Using mRNA prepared from SiRNA-APP and SHSY5Y cells, we deter-
mined the effects of reduced APP on 9 genes: Drp1, Fis1, Mfn1, Mfn2,
Opa1, VDAC1, ANT, CypD, and BclXL (Table 2). We also measured
Fig. 1. Immunoblotting analysis of SiRNA-APP, SiRNA-Tau, and SiRNA-VDAC1 SHSY5Y cells relative to SHSY5Y cells. Signiﬁcantly decreased levels of APP, Tau, and VDAC1 proteins were
found in SiRNA-APP, SiRNA-Tau, and SiRNA-VDAC1 SHSY5Y cells relative to the SHSY5Y cells.
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nases in human neuroblastoma cells.
In the SiRNA-APP (SHSY5Y) cells compared to the SHSY5Y cells,
mRNA expression levels were signiﬁcantly decreased in Drp1, by 1.3
fold (P = 0.02) and in Fis1, by 1.5 fold (P = 0.002). In contrast, the
mRNA expression levels of Mfn1 were signiﬁcantly increased (2.2 fold,
P = 0.001), as were levels of Mfn2 (1.7 fold, P = 0.005) and Opa1 (1.1
fold, P = 0.17) in the SiRNA-APP cells compared to the SHSY5Y cells
(Table 2). Thus, the reduction of APP corresponded to a reduction in
ﬁssion, in the SiRNA-APP cells. Interestingly, themitochondria permeabil-
ity transition pore-encoded genes were signiﬁcantly down-regulated
in the SiRNA-APP cells relative to the SHSY5Y cells: VDAC1, by 1.3 fold
(P = 01); ANT, by 1.6 fold (P = 0.02); and CypD, by 2.3 fold (P =
0.002). Interestingly, in measuring the mRNA levels of hexokinase 1
and 2, we found signiﬁcantly increased levels in hexokinase 1 (1.4 fold,
P = 0.04) in the SiRNA-APP cells relative to the SHSY5Y cells. We did
not observe a signiﬁcant change in mRNA levels of hexokinase 2.
3.2. APP: electron transport chain genes
As shown in Table 2, decreased levels of mRNA expression were
found in Complex III (CytB, 1.2 fold, P = 0.06) and Complex IV (COX1,
1.3 fold, P = 0.07; COX2, 1.3 fold, P = 0.12) in the SiRNA-APP cells
relative to the SHSY5Y cells. In contrast, signiﬁcantly increased levels
of mRNA were found for ND6 (1.5 fold, P = 0.04) and for ATPase (1.4
fold, P = 0.03) genes in the SiRNA-APP cells relative to the SHSY5Y
cells.
3.3. APP: AD-related genes
The levels of mRNA expression were signiﬁcantly decreased for
APP (1.6 fold, P = 0.004), Tau (1.1 fold, P = 0.09, not signiﬁcant),BACE1 (1.5 fold, P = 0.003), PS1 (1.4 fold, P = 0.02), and PS2 (1.4
fold, P = 0.03) in the SiRNA-APP cells relative to the SHSY5Y cells
(Table 2). These results suggest that reduced APP may be beneﬁcial to
AD because reduced expression of AD-related genes inhibit apoptotic
cell death and oxidative stress. We also found decreased levels
of mRNA for both GSK3β (1.3 fold, P = 0.2) and GSK3α (1.1 fold,
P = 0.1, not signiﬁcant).
3.4. APP: synaptic genes
mRNA expression was signiﬁcantly increased for synaptophysin
(1.6 fold, P = 0.01), synapsin 1 (1.3 fold, P = 0.09, not signiﬁcant),
synapsin 2 (4.6 fold, P = 0.001), synaptobrevin 1 (2.5 fold, P = 0.003),
synaptobrevin 2 (3.5 fold, P = 0.001), GAP43 (3.3 fold, P = 0.001),
and neurogranin (3.1 fold, P = 0.001) in the SiRNA-APP cells relative
to the SHSY5Y cells (Table 2). The levels of mRNA expression were in-
creased signiﬁcantly for the postsynaptic genes synaptopodin (2.8 fold,
P = 0.002) and PSD95 (2.4 fold, P = 0.003). These ﬁndings suggest
that reduced APP may be beneﬁcial for maintaining synaptic activity in
SHSY5Y cells.
3.5. Tau: mitochondrial structural genes
In the SiRNA-Tau cells compared to the SHSY5Y cells, mRNA expres-
sion levels were decreased in Drp1 by 1.2 fold (not signiﬁcant); and in
Fis1, by 1.3 fold (P = 0.03) (Table 2). In contrast, the mRNA expression
levels of Mfn1 increased (1.2 fold, P = 0.15, not signiﬁcant), Mfn2
(1.4 fold, P = 0.02), and Opa1 (1.5 fold, P = 0.03) in the SiRNA-Tau
cells compared to the SHSY5Y cells (Table 2). Thus, the reduction
of Tau corresponded to a reduction in ﬁssion and increased fusion in
the SiRNA-Tau cells. The mitochondrial permeability transition pore-
encoded genes were signiﬁcantly down-regulated in the SiRNA-Tau
Fig. 2.Mitochondrial functional parameters in SiRNA-APP SHSY5Y cells relative to control SHSY5Y cells. (A)H2O2 signiﬁcantlydecreased inSiRNA-APP cells relative to SHS5Y cells. (B) Lipid
peroxidation levels signiﬁcantly decreased in SiRNA-APP cells relative to SHS5Y cells. (C) GTPase Drp1 activity signiﬁcantly decreased in SiRNA-APP cells relative to SHS5Y cells. (D) Cy-
tochrome c oxidase activity signiﬁcantly increased in SiRNA-APP cells relative to SHS5Y cells. (E) ATP levels signiﬁcantly increased in SiRNA-APP cells relative to SHS5Y cells.
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1.5 fold (P = 0.01); and CypD, by 1.7 fold (P = 0.03).We found slightly
increased levels ofmRNA for hexokinase 1 (1.1 fold, not signiﬁcant) and
hexokinase 2 (1.1 fold, not signiﬁcant) in the SiRNA-APP cells relative to
the SHSY5Y cells.
3.6. Tau: electron transport chain genes
As shown in Table 2, signiﬁcantly decreased levels of mRNA expres-
sion were found in Complex III (CytB, 1.5 fold, P = 0.02) and Complex
IV (COX1, 1.7 fold, P = 0.02; COX2, 1.4 fold, P = 0.04) in the SiRNA-
Tau cells relative to the SHSY5Y cells. These ﬁndings suggest that reduced
Tau may slow down the functioning of the ETC.
3.7. Tau: AD-related genes
The levels of mRNA expression were signiﬁcantly decreased for
APP (1.7 fold, P = 0.003), Tau (1.4 fold, P = 0.03), BACE1 (1.8 fold,
P = 0.002), PS1 (1.8 fold, P = 0.001), and PS2 (1.7 fold, P = 0.04)
(Table 2). These results indicate that reduced Tau may be beneﬁcial in
patients with AD because reduced expression of AD-related genes
may reduce Aβ and/or induce a Tau-induced cascade of cellular
changes. We found decreased levels of mRNA for both GSK3β (by 1.3
fold, P = 0.04) and GSK3α (1.5 fold, P = 0.02), indicating that reduced
GSK3α and GSK3β levels may protect against toxic insults of Aβ and
phosphorylated Tau in AD neurons.
3.8. Tau: synaptic genes
mRNA expression levels were increased in synaptophysin (1.8 fold,
P = 0.002), synapsin 1 (2.2 fold, P = 0.002), synapsin 2 (2.0 fold,P = 0.003), synaptobrevin 1 (4.2 fold, P = 0.001), synaptobrevin 2
(1.3 fold, P = 0.15, not signiﬁcant), GAP43 (4.4 fold P = 0.001), and
neurogranin (1.4 fold, P = 0.04) in SiRNA-Tau cells relative to SHSY5Y
cells (Table 2). The levels of mRNA expression were increased, but not
signiﬁcantly, for synaptopodin (1.6 fold, P = 0.03) and PSD95 (1.3 fold,
P = 0.04). These ﬁndings suggest that reduced Tau is beneﬁcial for
maintaining synaptic activity in SHSY5Y cells.
3.9. VDAC1: mitochondrial structural genes
As shown in Table 2, mRNA expression levels were signiﬁcantly
decreased in Drp1, by 1.3 fold (not signiﬁcant) and in Fis1, by 1.2 fold
(not signiﬁcant) in the SiRNA-VDAC1 cells compared to the SHSY5Y
cells. In contrast, the mRNA expression levels of Mfn1 increased signiﬁ-
cantly (1.5 fold, P = 0.01), as did Mfn2 (1.8 fold, P = 0.001) and in the
SiRNA-VDAC1 cells compared to the SHSY5Y cells (Table 2). Interes-
tingly, the mitochondrial permeability transition pore-encoded genes
were signiﬁcantly down-regulated in the SiRNA-VDAC1 cells relative
to the SHSY5Y cells: VDAC1, by 1.8 fold (P = 0002); ANT, by 1.9 fold
(P = 0.003); and CypD, by 1.2 fold (P = 0.06). We also measured
mRNA levels of hexokinases 1 and 2. We found increased levels of
mRNA in hexokinase 1 (1.2 fold, not signiﬁcant) and hexokinase 2
(1.1 fold, not signiﬁcant) in the SiRNA-VDAC1 cells relative to the
SHSY5Y cells.
3.10. VDAC1: electron transport chain genes
Decreased levels of mRNA expressions were found in Complex III
(CytB, 1.1 fold, P = 0.12) and Complex IV (COX1, 1.3 fold [P = 0.08];
COX2, by 1.2 fold [P = 0.09, not signiﬁcant]) in the SiRNA-APP relative
to the SHSY5Y cells (Table 2).
Fig. 3.Mitochondrial functional parameters in SiRNA-Tau SHSY5Y cells relative to SHSY5Y cells. (A)H2O2 signiﬁcantly decreased in SiRNA-Tau cells relative to control SHS5Y cells. (B) Lipid
peroxidation levels signiﬁcantly decreased in SiRNA-Tau cells relative to SHS5Y cells. (C) GTPase Drp1 activity signiﬁcantly decreased in SiRNA-Tau cells relative to SHS5Y cells. (D) Cyto-
chrome c oxidase activity signiﬁcantly increased in SiRNA-Tau cells relative to SHS5Y cells. (E) ATP levels signiﬁcantly increased in SiRNA-Tau cells relative to SHS5Y cells.
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As shown in Table 2, levels of mRNA expression were signiﬁcantly
decreased for APP (by 1.4 fold, P = 0.02), Tau (by 1.2 fold, P = 0.08,
not signiﬁcant), BACE1 (1.4 fold, P = 0.03), PS1 (1.6 fold, P = 0.01),
and PS2 (1.6 fold, P = 0.03) in the SiRNA-VDAC1 cells relative to the
SHSY5Y cells, indicating that reduced VDAC1 decreases AD-related
genes in AD progression. We also measured mRNA levels of GSK3α
and GSK3β in SiRNA-VDAC1 cells relative to the SHSY5Y cells and
found decreased levels of mRNA in both GSK3β (by 1.2 fold, P = 0.09,
not signiﬁcant) and GSK3α (1.3 fold, P = 0.04), suggesting that reduced
GSK3α and GSK3βmay protect cells against toxic insults of VDAC1, Tau,
and Aβ.
3.12. VDAC1: synaptic genes
The levels of mRNA expression were signiﬁcantly increased for
synaptophysin (1.6 fold, P = 0.03), synapsin 1 (2.7 fold, P = 0.001),
synapsin 2 (1.8 fold, P = 0.004), synaptobrevin 1 (1.4 fold, P = 0.04),
synaptobrevin 2 (2.8 fold, P = 0.002), GAP43 (1.2 fold P = 0.25, not
signiﬁcant), and neurogranin (1.6 fold, P = 0.02) in the SiRNA-VDAC1
cells relative to the SHSY5Y cells (Table 2). The levels of mRNA expres-
sionwere signiﬁcantly increased for synaptopodin (1.9 fold, P = 0.003)
and PSD95 (1.4 fold, P = 0.04). These ﬁndings suggest that reduced
VDAC1 is beneﬁcial for maintaining synaptic activity in SHSY5Y cells.
3.13. Immunoblotting analysis
To determine whether reduced RNA levels of APP, Tau, and VDAC1
are translated into the proteins we performed immunoblotting analysis
of APP, Tau, and VDAC1 genes using protein lysates prepared fromSiRNA-APP, SiRNA-Tau, SiRNA-VDAC1, and SHSY5Ycells. As shown in
Fig. 1, we found signiﬁcantly decreased APP protein levels in SiRNA-
APP cells relative to the SHSY5Y cells (P = 0.004), indicating that
reducedmRNA levels in SiRNA-APP cells are also reﬂected in the protein
level. Similar to APP, the Tau and VDAC1 protein levels were also signif-
icantly decreased in SiRNA-Tau (P = 0.001) and SiRNA-VDAC1 (P =
0.001) cells relative to the SHSY5Y cells.
3.14. Mitochondrial function
To determine whether RNA silencing of APP, Tau, and VDAC1 genes
affects mitochondrial function in the SHSY5Y cells, we characterized
mitochondrial function by measuring H2O2 production, cytochrome
oxidase activity, ATP production, lipid peroxidation, and ﬁssion-linked
GTPase enzymatic activity in SiRNA-APP cells, SiRNA-Tau cells, SiRNA-
VDAC1 cells, and control SHSY5Y cells.
3.14.1. Mitochondrial function in SiRNA-APP cells
Signiﬁcantly decreased levels of H2O2 were found in isolated mito-
chondria from SiRNA-APP cells relative to the levels of H2O2 in the
SHSY5Y cells (P = 0.001) (Fig. 2A), suggesting that reduced APP may
reduce the production of mitochondrial H2O2production in SiRNA-APP
cells.
4-Hydroxy-nonenol levels were signiﬁcantly reduced (P = 0.01) in
the SiRNA-APP cells relative to the levels of 4-hydroxy-nonenol in the
SHSY5Y cells (Fig. 2B), indicating that reduced APP corresponded to
reduced lipid peroxidation in the SiRNA-APP cells.
As shown in Fig. 2C, GTPase Drp1 enzymatic activity was signiﬁcant-
ly reduced in the SiRNA-APP cells (P = 0.03) relative to this activity in
the SHSY5Y cells, indicating that reduced APPmay reducemitochondri-
al fragmentation in SHSY5Y cells.
Fig. 4.Mitochondrial functional parameters in SiRNA-VDAC1 SHSY5Y cells relative to SHSY5Y cells. (A) H2O2 signiﬁcantly decreased in SiRNA-VDAC1 cells relative to SHS5Y cells. (B) Lipid
peroxidation levels signiﬁcantly decreased in SiRNA-APP cells relative to SHS5Y cells. (C) GTPase Drp1 activity signiﬁcantly decreased in SiRNA-VDAC1 cells relative to SHS5Y cells. (D)
Cytochrome c oxidase activity signiﬁcantly increased in SiRNA-VDAC1 cells relative to SHS5Y cells. (E) ATP levels signiﬁcantly increased in SiRNA-VDCA1 cells relative to SHS5Y cells.
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phosphorylation, was signiﬁcantly higher (P = 0.03) in the SiRNA-APP
cells relative to cytochrome oxidase activity in the SHSY5Y cells
(Fig. 2D), indicating that reduced APP may enhance cytochrome c
oxidase activity.
Mitochondrial ATP levels were signiﬁcantly increased in SiRNA-APP
cells (P = 0.02) relative tomitochondrial ATP levels in the SHSY5Y cells
(Fig. 2E), indicating that reduced APP is beneﬁcial to SHSY5Y cells.
These functional analyses suggest that a partial reduction of APP
enhances mitochondrial function in SHSY5Y cells.3.14.2. Mitochondrial function in SiRNA-Tau cells
Signiﬁcantly decreased levels of H2O2 were found in the SiRNA-Tau
cells relative to the levels of H2O2 in the SHSY5Y cells (P = 0.001)
(Fig. 3A). These ﬁndings suggest that reduced Tau mRNA expression
inﬂuences H2O2 levels in SHSY5Y cells.
4-Hydroxy-nonenol was signiﬁcantly reduced (P = 0.01) in the
SiRNA-Tau cells relative to the SHSY5Y cells (Fig. 3B), indicating that
reduced Tau expression corresponded to reduced lipid peroxidation in
the SiRNA-Tau cells and may likely inﬂuence the reduction of lipid
peroxidation levels.
As shown in Fig. 3C, GTPase Drp1 enzymatic activity was signiﬁcant-
ly reduced in the SiRNA-Tau cells (P = 0.03) relative to GTPase Drp1
enzymatic activity in the SHSY5Y cells, indicating that reduced Tau
may decrease mitochondrial fragmentation in SHSY5Y cells.
Cytochrome oxidase activity was signiﬁcantly increased (P = 0.03)
in the SiRNA-Tau cells relative to cytochrome oxidase activity in theSHSY5Y cells (Fig. 3D), indicating that reduced Tau may enhance
cytochrome c oxidase activity.
Mitochondrial ATP levels were increased in the SiRNA-Tau cells
(P = 0.02) relative to the levels in the SHSY5Y cells (Fig. 3E), indicating
that reduced Tau may enhance ATP levels in SHSY5Y cells.
These ﬁndings suggest that a partial reduction of Tau may boost
mitochondrial function in SHSY5Y cells.3.14.3. Mitochondrial function in SiRNA-VDAC1 cells
Signiﬁcantly reduced levels of H2O2were found in the SiRNA-VDAC1
cells relative to H2O2 levels in the SHSY5Y cells (P = 0.01) (Fig. 4A),
suggesting that reduced VDAC1 may be responsible for low mitochon-
drial H2O2 production.
4-Hydroxy-2-nonenol was signiﬁcantly reduced (P = 0.01) in the
SiRNA-Tau cells relative to -4-hydroxy-nonenol in the SHSY5Y cells
(Fig. 4B), suggesting that reduced VDAC1 may have a role in decreased
lipid peroxidation in SHSY5Y cells.
GTPase Drp1 enzymatic activity was signiﬁcantly decreased in the
SiRNA-VDAC1 cells (P = 0.01) relative to the activity in the SHSY5Y
cells (Fig. 4C), indicating that reduced VDAC1 may decrease mitochon-
drial fragmentation in SHSY5Y cells.
Cytochrome oxidase activity was signiﬁcantly increased (P = 0.01)
in the SrRNA-VDAC1 cells relative to cytochrome oxidase activity in the
SHSY5Y cells (Fig. 4D), indicating that reduced VDAC1 may enhance
cytochrome c oxidase activity.
Mitochondrial ATP levels were signiﬁcantly increased in SiRNA-
VDAC1 cells (P = 0.04) relative to mitochondrial ATP levels in the
2376 M. Manczak, P.H. Reddy / Biochimica et Biophysica Acta 1832 (2013) 2368–2378SHSY5Y cells (Fig. 4E), indicating that reduced VDAC1may enhanceATP
levels in SHSY5Y cells.
4. Discussion
The objective of our study was to better understand the effects of
mRNA silencing of APP, Tau, and VDAC1 genes on mitochondrial func-
tion and synaptic activity in SHSY5Y cells that express APP, Tau, and
VDAC1. We studied human brain tumor-derived SHSY5Y cells because
of their known relevance to human cells. We silenced mRNA levels of
APP, Tau, and VDAC1, and studied mRNA levels of 34 genes that are
involved in AD progression, mitochondrial dynamics, and synaptic
activity. We also assessed the effects of silencing APP, Tau, and VDAC1
genes on mitochondrial function and GTPase enzymatic activity.
We found that a reduction in APP, Tau, and VDAC1 gene expressions
improved mitochondrial function and synaptic activity, and reduced
expressions of several AD-related genes.
Our real-timeRT-PCR analysis of 34 genes (see Table 2) and immuno-
blotting analysis (Fig. 1) revealed that RNA silencing of APP, Tau, and
VDAC1 genes in SHSY5Y cells was successful in reducing mRNA and
protein levels of APP, Tau, and VDAC1 genes. SHSY5Y cells with mRNA-
silenced APP, Tau, and VDAC1 exhibited increased synaptic gene expres-
sions, enhancedmitochondrial function, and reducedGTPase Drp1 enzy-
matic activity relative to the control SHSY5Y cells, all ofwhich are known
to be beneﬁcial for synaptic activity and mitochondrial function. Effects
from the silencing of mitochondria and synaptic activity were even
stronger in APP and Tau genes. These ﬁndings lead us to conclude that
the reduction of APP, Tau, and VDAC1 genes may be protective against
APP-, Tau-, and VDAC1-induced toxic insults that occur in AD.
Several lines of evidence support our current study ﬁndings and our
hypothesis that a partial reduction of APP, Tau, and VDAC1 genes is like-
ly to increase synaptic activity and enhance mitochondrial function.
1) Increased VDAC1 expression has been linked to mitochondrial
dysfunction and apoptotic cell death [62–66]. In a recent genetic
study, the Reddy laboratory found increased VDAC1 levels in post-
mortem brain tissues from AD patients and APP mice. Further, we
also found that increased VDAC1 interacts with Aβ and forms
VDAC1–Aβ complexes. These abnormal complex formations were
increased in a progression-dependent manner in AD pathogenesis.
Our mitochondrial functional analysis of brain sections from 6-, 12-,
and 20-month-old mice revealed increased levels of free radical
production, lipid peroxidation, ﬁssion-linked GTPase enzymatic
activity, reduced cytochrome oxidase activity, and mitochondrial
ATP production in APP mice, strongly suggesting that VDAC1–Aβ
complexes may be responsible for defective mitochondrial function
in AD progression in APP transgenicmice [56]. Based on these previ-
ous study ﬁndings, we proposed that a partial reduction of VDAC1
and/or wild-type or mutant APP in neurons may reduce VDAC1–
Aβ complex formations. In turn, these reduced VDAC1–Aβ complex
formations may protect cells from toxic insults of excessive VDAC1
and APP/Aβ.
In the current study, we tested our hypothesis and found that par-
tial reduction of VDAC1-RNA enhanced mitochondrial function
(Fig. 2) and synaptic activity, evidenced by increased levels of synap-
tic genes in SiRNA-VDAC1 cells (Table 2). Mechanistically, age-
dependent, increased levels of VDAC1 and APP are toxic, and a
partial reduction of VDAC1 and/or APP may be beneﬁcial and may
protect neurons in AD pathogenesis. Findings from our previous
VDAC1 study of APP mice [56] and this current study lead us to
propose that genetic crossings of VDAC1 heterozygote knockout
(VDAC1+/−) mice with APP transgenic mice and VDAC1+/−
mice with Tau transgenic may reveal in vivo protective aspects of
VDAC1 reduction in AD pathogenesis, such as improvement in cog-
nition, reductions of Aβ & Tau pathologies, and enhanced function
in mitochondria and synapses.2) Age-dependent, increased levels of full-lengthAPP andAβproduction
have been reported to cause synaptic damage andmitochondrial dys-
function in AD patients and transgenic mice that express Aβ muta-
tions [4–7,30,41,56,67,68]. Extensive studies of APP/Aβ and in
mitochondria revealed that APP and Aβ are associated with mito-
chondrial membranes and that they induce excessive amounts of
free radical production, reduce cytochromeoxidase activity, causemi-
tochondrial dysfunction, and inhibit ATP production in AD neurons
[4,5,13,29]. Further, recent biochemical studies of Aβ revealed that
the interaction of Aβ with several mitochondrial proteins (including
CypD, ABAD, and Drp1) forms abnormal complexes of CypD-Aβ,
ABAD-Aβ, and Drp1-Aβ [6,7,41]. These complexes are critically re-
sponsible for mitochondrial dysfunction, defective mitochondrial ax-
onal transport, and synaptic damage in AD neurons. In addition, the
excessive accumulation of Aβ at synapses and synaptic mitochondria
cause synaptic damage and synaptic oxidative stress in AD neurons
[4,5,13,29].
In contrast, reducedmutant APP/Aβ orwild-type APP in cells and APP
transgenic mice was found to result in reduced synaptic toxicity and
reduced mitochondrial dysfunction [46–49]. Our current ﬁndings –
that a partial reduction of APP in human cells enhancesmitochondrial
function and synaptic activity – further support earlier studies
[46–49]. In addition, our current ﬁndings may provide important
clues for RNA-silencing therapeutic strategies of APP for AD patients.
3) Age-dependent, increased levels of full-length mutant Tau and/
or wild-type Tau have been found to cause impaired axonal
transport, and synaptic and mitochondrial deﬁciencies in AD
[38,69–75]. Tau hyperphosphorylation and neuroﬁbrillary tangles
are associated with several late-onset neurodegenerative diseases,
such as AD, amyotrophic lateral sclerosis, argyrophilic grain demen-
tia, corticobasal degeneration, Cruetfedt–Jacob disease, dementia
pugilistica, diffuse NFTs with calciﬁcation, Down's syndrome,
fronto-temporal dementia, Gerstmann–Straussler–Scheinker dis-
ease, Hallervorden–Spatz disease, myotonic dystrophy, Neimann–
Pick disease-type C, non-Guamanian motor neuron disease with
NFTs, Pick's disease, postencephalitic parkinsonism, prion pro-
tein cerebral angiopathy, progressive cortical gliosis, progressive
supranuclear palsy, subacute sclerosing panencephalitis, and
tangle-only dementia [76]. Reduced levels of normal Tau and phos-
phorylated Tau have been suggested as a therapeutic approach for
patients with AD and other Tauopathies. Further, several recent
studies revealed that reduced Tau has been found to increase axonal
transport of mitochondria and synaptic activity, and to reduce Aβ
levels and Aβ-induced toxicity [77,78]. Together, these results lead
us to propose that reduced levels of normal and phosphorylated
Tau may reduce mitochondrial oxidative insults and synaptic dam-
age to neurons that are involved in AD and other Tauopathies.
4) Signiﬁcantly reduced levels of ﬁssion-linked GTPase Drp1 activity in
SiRNA-APP, SiRNA-Tau, and SiRNA-VDAC1 cells may be related to
the reduction of APP, Tau, and VDAC1 in SHSY5Y cells. This possibil-
ity is strongly supported by an increase in VDAC1 and APP/Aβ ex-
pression levels that we found in AD postmortem brains and APP
transgenic mice [56]. Also, increased mitochondrial dysfunction
may be related to an increase in GTPase activity, mitochondrial
fragmentation, and apoptosis — a possibility that is supported by
research that found increased GTPase activity and excessive mito-
chondrial fragmentation in postmortem brain tissues from AD and
HDpatients, and AD and HD transgenicmice [61,79]. The correspon-
dences among increased GTPase activity, mitochondrial fragmenta-
tion, and reduced APP, Tau, and VDAC1 are supported by our real-
time RT-PCR data on mitochondrial dynamics: reduced APP, Tau,
and VDAC1 correspond to increased mRNA levels of Mfn1 and
Mfn2, and decreased mRNA levels of Drp1 and Fis1 in the SiRNA-
APP, SiRNA-Tau, and SiRNA-VDAC1 cells.
The signiﬁcantly increasedmRNA levels that we found in the synap-
tic genes (Table 2) of the RNA-silenced APP, Tau, and VDAC1 in
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are beneﬁcial for synaptic activity in human neurons. Findings from
our current study support our previous study, in which increased
APP and Aβ levels in cortical tissues from APP mice correlated with
reduced synaptic and mitochondrial activity at different stages in
AD progression [30,33,41,56,79]. Our current ﬁndings also suggest
that reduced APP, Tau, and VDAC1 are beneﬁcial not only to neurons
that are affected by AD but also to neurons not in a diseased state.
Additional studies are needed to further evaluate reduced APP,
Tau, and VDAC1 as possible therapeutic approaches to treat persons
with AD.
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